{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Grade 0 acute GVHD"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Grade I acute GVHD"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Grade II acute GVHD"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Grade III acute GVHD"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Grade IV acute GVHD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Number of participants who developed acute GVHD post-transplant, aGVHD stages:\n\nSkin: a maculopapular eruption involving \\< 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation\n\nLiver:\n\nbilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin \\> 15 mg/100 mL\n\nGut:\n\nDiarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.\n\naGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)","id":"OG000","title":"Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.","reportingStatus":"POSTED","timeFrame":"Up to 84 days post-transplant","title":"Rates of Acute GvHD","type":"SECONDARY","unitOfMeasure":"Participants"}